[
Aguirre GA, Rodriguez De Ita J, de la Garza RG, Castilla-Cortazar I. Insulin-like growth factor 1 deficiency and metabolic syndrome. J Transl Med 14, 3, 2016.
]Search in Google Scholar
[
Aguirre GA, Gonzalez-Guerra JL, Espinosa L, Castilla-Cortazar I. Insulin-like growth factor 1 in the cardiovascular system. Rev Physiol Biochem Pharmacol 175, 1–45, 2018.
]Search in Google Scholar
[
Arturi F, Succurro E, Procopio C, Pedace E, Mannino GC, Lugara M, Procopio T, Andreozzi F, Sciacqua A, Hribal ML, Perticone F, Sesti G. Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 96, E1640–E1644, 2011.
]Search in Google Scholar
[
Berryman DE, Glad CAM, List EO, Johannsson G. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat Rev Endocrinol 9, 346–356, 2013.
]Search in Google Scholar
[
Clemmons DR. The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Investig 113, 25–27, 2004.
]Search in Google Scholar
[
Clemmons DR. Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol 6, 620–625, 2006.
]Search in Google Scholar
[
Clemmons DR, Moses AC, Sommer A, Jacobson W, Rogol AD, Sleevi MR, Allan G. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 15, 265–274, 2005.
]Search in Google Scholar
[
Cornford AS, Barkan AL, Horowitz JF. Rapid suppression of growth hormone concentration by overeating: Potential mediation by hyperinsulinemia. J Clin Endocrinol Metab 96, 824–830, 2011.
]Search in Google Scholar
[
De Ita JR, Castilla-Cortazar I, Aguirre GA, Sanchez-Yago C, Santos-Ruiz MO, Guerra-Menendez L, Martin-Estal I, Garcia-Magarino M, Lara-Diaz VJ, Puche JE, Munoz U. Altered liver expression of genes involved in lipid and glucose metabolism in mice with partial IGF-1 deficiency: an experimental approach to metabolic syndrome. J Transl Med 13, 326–346, 2015.
]Search in Google Scholar
[
Ferrari U, Schmidmaier R, Jung T, Reincke M, Martini S, Schoser B, Bidlingmaier M, Drey M. IGF-I/IGFBP3/ALS deficiency in sarcopenia: Low GHBP suggests GH resistance in a subgroup of geriatric patients. J Clin Endocrinol Metab 106, e1698–e1707, 2021.
]Search in Google Scholar
[
Franco C, Bengtsson BA, Johannsson G. The GH/IGF-1 axis in obesity: physiological and pathological aspects. Metab Syndr Relat Disord 4, 51–56, 2006.
]Search in Google Scholar
[
Friedrich N, Jorgensen T, Juul A, Spielhagen C, Nauck M, Wallaschofski H, Linneberg A. Insulin-like growth factor I and anthropometric parameters in a Danish population. Exp Clin Endocrinol Diabetes 120, 171–174, 2012.
]Search in Google Scholar
[
Frystyk J. Free insulin-like growth factors measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 14, 337–75, 2004.
]Search in Google Scholar
[
Fusco A, Miele L, D’Uonnolo A, Forgione A, Riccardi L, Cefalo C, Barini A, Bianchi A, Giampietro A, Cimino V, Landolfi R, Grieco A, De Marinis L. Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. Clin Endocrinol 77, 531–536, 2012.
]Search in Google Scholar
[
Garcia-Fernandez M, Delgado G, Puche JE, Gonzalez-Baron S, Cortazar IC. Low doses of insulin-like growth factor I improve insulin resistance, lipid metabolism, and oxidative damage in aging rats. Endocrinology 149, 2433–2442, 2008.
]Search in Google Scholar
[
Ginsberg S, Laron Z, Bed MA, Vaisman N. The obesity of patients with Laron syndrome is not associated with excessive nutritional intake. Obes Res Clin Pract 3, 1–52, 2009.
]Search in Google Scholar
[
Gleeson HK, Lissett CA, Shalet SM. Insulin-like growth factor-I response to a single bolus of growth hormone is increased in obesity. J Clin Endocrinol Metab 90, 1061–1067, 2005.
]Search in Google Scholar
[
Gomez JM, Maravall FJ, Gomez N, Navarro MA, Casamitjana R, Soler J. The IGF-I system component concentrations that decrease with ageing are lower in obesity in relationship to body mass index and body fat. Growth Horm IGF Res 14, 91–96, 2004.
]Search in Google Scholar
[
Granata R. Peripheral activities of growth hormone-releasing hormone. J. Endocrinol Invest 39, 721–727, 2016.
]Search in Google Scholar
[
Haluzik M, Yakar S, Gavrilova O, Setser J, Boisclair Y, LeRoith. Insulin resistance in the liver-specific IGF-I gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex: relative roles of growth hormone and IGF-I in insulin resistance. Diabetes 52, 2483–2489, 2003.
]Search in Google Scholar
[
Hribal ML, Procopio T, Petta S, Sciacqua A, Grimaudo S, Pipitone RM, Perticone F, Sesti G. Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 98, E304–E308, 2013.
]Search in Google Scholar
[
Ichikawa T, Nakao K, Hamasaki K, Furukawa R, Tsuruta S, Ueda Y, Taura N, Shibata H, Fujimoto M, Toriyama K, Eguchi K. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int 1, 287–294, 2007.
]Search in Google Scholar
[
Kong AP, Choi KC, Wong GW, Ko GT, Ho CS, Chan MH, Ozaki R, Ma RC, Lau JT, Chan JC. Serum concentrations of insulin-like growth factor-I, insulin-like growth factor binding protein-3 and cardiovascular risk factors in adolescents. Ann Clin Biochem 48, 263–269, 2011.
]Search in Google Scholar
[
Kotronen A, Lewitt M, Hall K, Brismar K, Yki-Jarvinen H. Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. J Clin Endocrinol Metab 98, 4867–4872, 2008.
]Search in Google Scholar
[
Kreitschmann-Andermahr I, Suarez P, Jennings R, Evers N, Brabant G. GH/IGF-I regulation in obesity–mechanisms and practical consequences in children and adults. Horm Res Paediatr 73, 153–160, 2010.
]Search in Google Scholar
[
Lam CSP, Chen MH, Lacey SM, Yang Q, Sullivan LM, Xanthakis V, Safa R, Smith HM, Peng X, Sawyer DB, Vasan RS. Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community. Arterioscler Thromb Vasc Biol 30, 1479–1484, 2010.
]Search in Google Scholar
[
Lee EK, Gorospe M. Minireview: Posttranscriptional regulation of the insulin and insulin-like growth factor systems. Endocrinology 151, 1403–1408, 2010.
]Search in Google Scholar
[
Lewitt MS, Hilding A, Ostenson CG, Efendic S, Brismar K, Hall K. Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. Diabetologia 51, 1135–1145, 2008.
]Search in Google Scholar
[
Lewitt MS, Dent MS, Hall K, Huang P. The insulin-like growth factor-system in obesity, insulin resistance and type 2 diabetes mellitus. J Clin Med 3, 1561–1574, 2014.
]Search in Google Scholar
[
Mallea-Gil MS, Ballarino MC, Spiraquis A, Iriarte M, Kura M, Gimenez S, Oneto A, Guitelman M, Machado R, Miguel CM. IGF-1 levels in different stages of liver steatosis and its association with metabolic syndrome. Acta Gastroenterol Latinoam 42, 20–26, 2012.
]Search in Google Scholar
[
Nishizawa H, Takahashi, M, Fukuoka H, Iguchi G, Kitazawa R, Takahashi Y. GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model. Biochem Biophys Res Commun 423, 295–300, 2012.
]Search in Google Scholar
[
O’Connell T, Clemmons DR. IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J Clin Endocrinol Metab 87, 4356–4360, 2002.
]Search in Google Scholar
[
Oh J, Kim JY, Park S, Youn JC, Son NH, Shin DJ, Lee SH, Kang SM, Jee SH, Jang Y. The relationship between insulin-like growth factor-1 and metabolic syndrome, independent of adiponectin. Clin Chim Acta 413, 506–510, 2012.
]Search in Google Scholar
[
Petaja EM, Zhou Y, Havana M, Hakkarainen A, Lundbom N, Ihalainen J, Yki-Jarvinen H. Phosphorylated IGFBP-1 as a noninvasive predictor of liver fat in NAFLD. Sci Rep 6, 24740, 2016.
]Search in Google Scholar
[
Petersson U, Ostgren CJ, Brudin L, Brismar K, Nilsson PM. Low levels of insulin-like growth factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): The soderakra cardiovascular risk factor study. Diabetes Metab 35, 198–205, 2009.
]Search in Google Scholar
[
Reinehr T, Kleber M, Toschke AM, Woelfle J, Roth CL. Longitudinal association between IGFBP-1 levels and parameters of the metabolic syndrome in obese children before and after weight loss. Int J Pediatr Obes 6, 236–243, 2011.
]Search in Google Scholar
[
Runchey SS, Boyko EJ, Ioannou GN, Utzschneider KM. Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States. J Gastroenterol Hepatol 29, 589–596, 2014.
]Search in Google Scholar
[
Savastano S, Barbato A, di Somma C, Guida B, Pizza G, Barrea L, Avallone S, Schiano di Cola M, Strazzullo P, Colao A. Beyond waist circumference in an adult male population of southern Italy: Is there any role for subscapular skinfold thickness in the relationship between insulin-like growth factor-I system and metabolic parameters? J Endocrinol Investig 35, 925–929, 2012.
]Search in Google Scholar
[
Saydah S, Ballard-Barbash R, Potischman N. Association of metabolic syndrome with insulin-like growth factors among adults in the US. Cancer Causes Control 20, 1309–1316, 2009.
]Search in Google Scholar
[
Saukkonen T, Shojaee-Moradie F, Williams RM, Amin R, Yuen KC, Watts A, Acerini CL, Umpleby AM, Dunger DB. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes. Diabetes 55, 2365–2370, 2006.
]Search in Google Scholar
[
Sesti G, Sciacqua A, Cardellini M, Marini MA, Maio R, Vatrano M, Succurro E, Lauro R, Federici M, Perticone F. Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care 28, 120–125, 2005.
]Search in Google Scholar
[
Sesti G, Fiorentino TV, Hribal ML, Sciacqua A, Perticone F. Association of hepatic insulin resistance indexes to non-alcoholic fatty liver disease and related biomarkers. Nutr Metab Cardiovasc Dis 23, 1182–1187, 2013.
]Search in Google Scholar
[
Schneider HJ, Saller B, Klotsche J, Marz W, Erwa W, Wittchen HU, Stalla GK. Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects. Eur J Endocrinol 154, 699–706, 2006.
]Search in Google Scholar
[
Schneider HJ, Friedrich N, Klotsche J, Schipf S, Nauck M, Volzke H, Sievers C, Pieper L, Marz W, Wittchen HU, Stalla GK, Wallaschofski H. Prediction of incident diabetes mellitus by baseline IGF1 levels. Eur J Endocrinol 164, 223–229, 2011.
]Search in Google Scholar
[
Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Malarstig A, Brismar K, Hamsten A, Fisher RM, Hellenius ML. IGF-I/IGFBP-3 ratio: a mechanistic insight into the metabolic syndrome. Clin Sci 116, 507–512, 2009.
]Search in Google Scholar
[
Teppala S, Shankar A. Association between serum IGF-1 and diabetes among US adults. Diabetes Care 33, 2257–2259, 2010.
]Search in Google Scholar
[
Thankamony A, Capalbo D, Marcovecchio ML, Sleigh A, Jorgensen SW, Hill NR, Mooslehner K, Yeo GS, Bluck L, Juul A, Vaag A, Dunger DB. Low circulating levels of IGF-1 in healthy adults are associated with reduced β-cell function, increased intramyocellular lipid, and enhanced fat utilization during fasting. J Clin Endocrinol Metab 99, 2198–2207, 2014.
]Search in Google Scholar
[
Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocar-dial infarction. Diabetes 50, 637–642, 2001.
]Search in Google Scholar
[
Xu M, Zheng XM, Jiang F, Qiu WQ. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease. J Cell Biochem 119, 5864–5874, 2018.
]Search in Google Scholar
[
Yakar S, Setser J, Zhao H, Stannard B, Haluzik M, Glatt V, Bouxsein ML, Kopchick JJ, LeRoith D. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 113, 96–105, 2004.
]Search in Google Scholar
[
Yuen KCJ, Dunger DB. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults. Diabetes Obes Metab 9, 11–22, 2007.
]Search in Google Scholar
[
Zhang Q, Zhang ZX, Fang Q, Gao FY, Zhao QL, Yang Y, Su HM, Liu YK. [Expression and significance of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in hepatocyte steatosis model]. Zhonghua Gan Zang Bing Za Zhi 20, 196–200, 2012.
]Search in Google Scholar
